Aggregated China Business Blogs



Simcere Acquires New Cancer Drug; Misses on Q3 Revenue

Aggregated Source: China Stocks News and Analysis from Seeking Alpha
November 27, 2007|

Simcere Pharmaceutical (SCR) extended its cancer therapeutic offerings by paying 32.6 million RMB ($4.4 million) to buy 86% of Nanjing Tung Chit Pharmaceutical Co., Ltd. (Tung Chit). Tung Chit makes and markets Jiebaisu, a first-to-market platinum-based nedaplatin injection.

Original URL: Click here to visit original article
Copyright China Stocks News and Analysis from Seeking Alpha

Print This Post Print This Post | Email This Page Email This Page
No Ratings Yet
Loading ... Loading ...

Related Info:
  • Simcere Buys Cancer Drug Company
  • Simcere’s Q1: Revenue Increases 26%
  • Abraxis Receives China Approval for Cancer Drug
  • Roche Chemo Drug Approved in China for Gastric Cancer
  • Simcere Reports Unimpressive Q3 Results

    • No Comments Yet »

    Your comment

    The following HTML tags are permitted:
    <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

    RSS RSS Feed for Comments on this Post |